Amylin Pharmaceuticals ( AMLN) and Alkermes ( ALKS)

Drug/indication: Exenatide once weekly for diabetes

Approval decision date: March 5

Exenatide once weekly is a long-acting version of Exenatide, a once-daily injectable diabetes drug marketed by Amylin and Eli Lilly ( LLY). Exenatide once weekly was developed with Alkermes' long-acting drug delivery technology; the company will receive royalties on the drug's sales.

If you liked this article you might like

Ardelyx Has Big Potential

Ardelyx Has Big Potential

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Here's Why XenoPort (XNPT) Stock is Continuing to Surge Today

Trending Tickers: XNPT, OLED, MON, TPUB

Trending Tickers: XNPT, OLED, MON, TPUB